While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...

We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

Ken Hall looks at three important considerations for investors looking to build a sizeable passive income for a better ...

The scrubbing of clinical trial-related pages is notable because of how it could affect the ways researchers both inside and ...

The pipeline will run for about 213 kilometres to a $7.4 billion polyethylene plant where construction started last September ...

Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...